DE69830492D1 - Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME) - Google Patents

Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)

Info

Publication number
DE69830492D1
DE69830492D1 DE69830492T DE69830492T DE69830492D1 DE 69830492 D1 DE69830492 D1 DE 69830492D1 DE 69830492 T DE69830492 T DE 69830492T DE 69830492 T DE69830492 T DE 69830492T DE 69830492 D1 DE69830492 D1 DE 69830492D1
Authority
DE
Germany
Prior art keywords
antibodies
medicines against
lymphocytic tumors
myeloma
excluding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830492T
Other languages
English (en)
Other versions
DE69830492T2 (de
Inventor
Yasuo Koishihara
Yasushi Yoshimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE69830492D1 publication Critical patent/DE69830492D1/de
Application granted granted Critical
Publication of DE69830492T2 publication Critical patent/DE69830492T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69830492T 1997-02-12 1998-02-12 Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME) Expired - Lifetime DE69830492T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP4141097 1997-02-12
JP4141097 1997-02-12
PCT/JP1998/000568 WO1998035698A1 (fr) 1997-02-12 1998-02-12 Remedes contre les tumeurs lymphocitaires

Publications (2)

Publication Number Publication Date
DE69830492D1 true DE69830492D1 (de) 2005-07-14
DE69830492T2 DE69830492T2 (de) 2006-03-16

Family

ID=12607597

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830492T Expired - Lifetime DE69830492T2 (de) 1997-02-12 1998-02-12 Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)

Country Status (20)

Country Link
US (2) US6503510B2 (de)
EP (1) EP0997152B1 (de)
KR (2) KR20000070989A (de)
CN (1) CN1191855C (de)
AT (1) ATE297219T1 (de)
AU (1) AU724133B2 (de)
BR (1) BR9811094A (de)
CA (1) CA2280875C (de)
DE (1) DE69830492T2 (de)
ES (1) ES2241114T3 (de)
HK (1) HK1026368A1 (de)
HU (1) HUP0001136A3 (de)
IL (1) IL131381A0 (de)
NO (1) NO993866L (de)
PL (1) PL190065B1 (de)
RU (1) RU2177805C2 (de)
SK (1) SK110099A3 (de)
TR (1) TR199901949T2 (de)
UA (1) UA65561C2 (de)
WO (1) WO1998035698A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442493B (en) * 1993-10-15 2001-06-23 Toshio Hirano A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
WO1999043703A1 (fr) * 1998-02-25 1999-09-02 Chugai Seiyaku Kabushiki Kaisha Technique de dosage immunochimique de l'anticorps anti-hm1.24
CN1370076A (zh) * 1999-08-23 2002-09-18 中外制药株式会社 Hm1.24抗原的表达增强剂
WO2002057316A1 (fr) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Nouvel anticorps monoclonal
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
WO2002072615A1 (fr) 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Methode de purification de proteines
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) * 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) * 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1475101B1 (de) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antikörper enthaltende pharmazeutische lösungen
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
BRPI0518279A2 (pt) * 2004-10-26 2008-11-11 Chugai Pharmaceutical Co Ltd anticorpo antiglipicam 3 tendo cadeia de aÇécar modificada
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
US20080299128A1 (en) 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
UA105760C2 (uk) 2007-10-16 2014-06-25 Ес-Бі-Ай Біотех Ко., Лтд. Антитіло проти bst2
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US9123149B2 (en) * 2013-03-15 2015-09-01 Columbia Insurance Company Expert color system for color selection with color harmony and color emotion intelligence
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
DE69229482T2 (de) 1991-04-25 1999-11-18 Chugai Seiyaku K.K., Tokio/Tokyo Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
TW442493B (en) 1993-10-15 2001-06-23 Toshio Hirano A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
CA2282631A1 (en) * 1997-02-28 1998-09-03 Chugai Seiyaku Kabushiki Kaisha Lymphocyte activation inhibitors
CA2305712A1 (en) 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural humanized antibody
JP4346116B2 (ja) 1997-10-14 2009-10-21 中外製薬株式会社 リンパ球系腫瘍に対する抗体の作用増強剤

Also Published As

Publication number Publication date
AU724133B2 (en) 2000-09-14
US20020037288A1 (en) 2002-03-28
US6503510B2 (en) 2003-01-07
RU2177805C2 (ru) 2002-01-10
UA65561A (en) 2000-08-15
TR199901949T2 (xx) 2000-01-21
CA2280875A1 (en) 1998-08-20
US20030113334A1 (en) 2003-06-19
KR100655979B1 (ko) 2006-12-08
EP0997152A4 (de) 2001-04-18
KR20030097614A (ko) 2003-12-31
HUP0001136A3 (en) 2002-02-28
NO993866D0 (no) 1999-08-11
ES2241114T3 (es) 2005-10-16
DE69830492T2 (de) 2006-03-16
PL335140A1 (en) 2000-04-10
ATE297219T1 (de) 2005-06-15
PL190065B1 (pl) 2005-10-31
KR20000070989A (ko) 2000-11-25
WO1998035698A1 (fr) 1998-08-20
HUP0001136A2 (hu) 2000-08-28
CN1191855C (zh) 2005-03-09
AU5956398A (en) 1998-09-08
BR9811094A (pt) 2000-07-18
EP0997152A1 (de) 2000-05-03
UA65561C2 (uk) 2004-04-15
CA2280875C (en) 2005-07-05
SK110099A3 (en) 2000-08-14
NO993866L (no) 1999-10-11
CN1250381A (zh) 2000-04-12
HK1026368A1 (en) 2000-12-15
EP0997152B1 (de) 2005-06-08
IL131381A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
ATE77556T1 (de) Stabilisierte humanprotein-praeparate.
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ATE399177T1 (de) Derivate therapeutischer peptide
EA199800946A1 (ru) Концентрированный препарат антител
ATE204467T1 (de) Orale darreichungsform
NO20025064D0 (no) RGO koblet til peptider
EP1354896A4 (de) Neuer monoklonaler antikörper
AU641736B2 (en) Delivery of agents
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine
MX9604786A (es) Composicion farmaceutica.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition